ABSTRACT
We reviewed 250 patients with carcinoma of the lip who were treated with radiation therapy during a 30-year period. Although radiation techniques underwent continued refinement, the radiation dose delivered to the tumor remained relatively constant. Nearly all tumors were squamous cell carcinoma (247/250) and located on the lower lip (240/250). Only 9% initially manifested lymph node metastases. The median survival was 13.8 years. Treatment failure occurred in 11% of patients. Surgery salvaged half of these patients. Eighteen patients died from carcinoma of the lip, and six others had persistent tumor when last seen. Our experience would support the work of others. Early lesions can be successfully managed by either surgical or radiation treatment. The intermediate tumors and those near the commissure are better handled by radiation. Late lesions and those with lymph node metastases challenge the best surgical and radiation techniques.
Subject(s)
Carcinoma, Basal Cell/therapy , Carcinoma, Squamous Cell/therapy , Lip Neoplasms/therapy , Adult , Age Factors , Aged , Carcinoma, Basal Cell/pathology , Carcinoma, Basal Cell/radiotherapy , Carcinoma, Basal Cell/surgery , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Humans , Lip Neoplasms/pathology , Lip Neoplasms/radiotherapy , Lip Neoplasms/surgery , Lymphatic Metastasis , Middle Aged , Neck Dissection , Neoplasm Staging , Precancerous Conditions , Prognosis , Retrospective StudiesSubject(s)
Head and Neck Neoplasms/radiotherapy , Plasmacytoma/radiotherapy , Adult , Aged , Drug Therapy, Combination , Glottis , Humans , Laryngeal Neoplasms/radiotherapy , Lymphatic Metastasis , Male , Maxillary Neoplasms/radiotherapy , Melphalan/therapeutic use , Middle Aged , Nasopharyngeal Neoplasms/radiotherapy , Neoplasm Metastasis , Prednisone/therapeutic use , Prognosis , RecurrenceABSTRACT
L-Asparaginase was added to vincristine and prednisone for induction of first remission in 815 children with acute lymphocytic or acute undifferentiated leukemia. This combination resulted in an overall remission rate of 93%. The addition of L-asparaginse to the standard induction regimen using prednisone and vincristine did not significantly increase the morbidity or mortality rate during the induction period. The most common side effect was transient L-asparaginase-induced hyperglycemia. The safe administration of L-asparaginase i.m. and the dose efficacy of 6000 I.U./sq m were confirmed. For these reasons, L-asparaginase should be combined with vincristine and prednisone for the initial induction of children with acute lymphocytic or acute undifferentiated leukemia.
Subject(s)
Asparaginase/therapeutic use , Leukemia, Lymphoid/drug therapy , Prednisone/therapeutic use , Vincristine/therapeutic use , Adolescent , Asparaginase/administration & dosage , Asparaginase/adverse effects , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Hyperglycemia/chemically induced , Infections/complications , Injections, Intramuscular , Leukemia/complications , Leukemia/drug therapy , Leukemia, Lymphoid/complications , Male , Prednisone/administration & dosage , Remission, Spontaneous , Vincristine/adverse effectsABSTRACT
A study of 77 consecutive cases of childhood rhabdomyosarcoma treated initially at the Children's Hospital of Los Angeles from 1950 to 1972 demonstrated an impressive improvement in survival of patients when intensive chemotherapy was occurred in Stage II and Stage III disease. Eight out of 9 patients with a primary lesion of the lower extremities developed intra-abdominal disease. A general approach for treatment of Stage II, III, and IV rhabdomyosarcoma is proposed which involves intensive chemotherapy, following biopsy, as the principle treatment, with radiation and surgery used as a adjuvants.
